[{"address1": "280 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 231 6625", "website": "https://www.alumis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 107, "companyOfficers": [{"maxAge": 1, "name": "Mr. Martin  Babler Ph.D.", "age": 59, "title": "President, CEO & Chairman", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 701760, "exercisedValue": 0, "unexercisedValue": 12229563}, {"maxAge": 1, "name": "Dr. David M. Goldstein Ph.D.", "age": 58, "title": "Chief Scientific Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 499700, "exercisedValue": 0, "unexercisedValue": 1831528}, {"maxAge": 1, "name": "Mr. Roy C. Hardiman J.D.", "age": 64, "title": "Chief Business & Strategy Officer", "yearBorn": 1960, "fiscalYear": 2023, "totalPay": 499700, "exercisedValue": 0, "unexercisedValue": 1694511}, {"maxAge": 1, "name": "Mr. John R. Schroer C.F.A.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sara  Klein", "age": 60, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Derrick  Richardson", "age": 54, "title": "Senior Vice President of People & Culture", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Claire  Langrish Ph.D.", "title": "Senior VP & Head of Immunology and Translational Science", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nunn Ph.D.", "title": "Senior VP of Pharmacology & Project Team Leader", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jorn  Drappa M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Bradley", "age": 59, "title": "Chief Development Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.59, "open": 5.33, "dayLow": 4.855, "dayHigh": 6.19, "regularMarketPreviousClose": 6.59, "regularMarketOpen": 5.33, "regularMarketDayLow": 4.855, "regularMarketDayHigh": 6.19, "forwardPE": -0.8828338, "volume": 1466875, "regularMarketVolume": 1466875, "averageVolume": 147571, "averageVolume10days": 180700, "averageDailyVolume10Day": 180700, "bid": 5.58, "ask": 5.81, "bidSize": 200, "askSize": 200, "marketCap": 308489408, "fiftyTwoWeekLow": 4.855, "fiftyTwoWeekHigh": 13.53, "fiftyDayAverage": 8.0052, "twoHundredDayAverage": 10.506503, "currency": "USD", "enterpriseValue": 27745760, "floatShares": 14737855, "sharesOutstanding": 47222400, "sharesShort": 2386759, "sharesShortPriorMonth": 2539735, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.043899998, "heldPercentInsiders": 0.01205, "heldPercentInstitutions": 0.74855006, "shortRatio": 19.27, "shortPercentOfFloat": 0.064, "impliedSharesOutstanding": 54407300, "bookValue": 6.404, "priceToBook": 0.8853842, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -238774000, "trailingEps": -4.39, "forwardEps": -6.2, "enterpriseToEbitda": -0.116, "52WeekChange": -0.50451124, "SandP52WeekChange": 0.21027291, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ALMS", "underlyingSymbol": "ALMS", "shortName": "Alumis Inc.", "longName": "Alumis Inc.", "firstTradeDateEpochUtc": 1719581400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "7bc517b3-133f-3f7c-b6dd-349f2d478c1b", "messageBoardId": "finmb_705657695", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.67, "targetHighPrice": 32.0, "targetLowPrice": 19.0, "targetMeanPrice": 27.4, "targetMedianPrice": 29.0, "recommendationMean": 1.16667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 361870016, "totalCashPerShare": 6.652, "ebitda": -239060000, "totalDebt": 31098000, "quickRatio": 10.797, "currentRatio": 11.259, "debtToEquity": 8.926, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]